Journal
SCIENCE
Volume 339, Issue 6117, Pages 286-291Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1232227
Keywords
-
Categories
Funding
- NIH/National Cancer Institute (NCI)
- Department of Defense
- Susan B. Komen Foundation
- Breast Cancer Research Foundation
- LIGUE Francaise Contre le Cancer
- Fondation pour la Recherche Medicale
- Institut National du Cancer (SIRIC)
- Fondation Gustave Roussy
- BIIR
- Baylor University Medical Center foundations
- Cancer Prevention Research Institute of Texas
- NIH/NCI
Ask authors/readers for more resources
There have been substantial advances in cancer diagnostics and therapies in the past decade. Besides chemotherapeutic agents and radiation therapy, approaches now include targeting cancer cell-intrinsic mediators linked to genetic aberrations in cancer cells, in addition to cancer cell-extrinsic pathways, especially those regulating vascular programming of solid tumors. More recently, immunotherapeutics have entered the clinic largely on the basis of the recognition that several immune cell subsets, when chronically activated, foster tumor development. Here, we discuss clinical and experimental studies delineating protumorigenic roles for immune cell subsets that are players in cancer-associated inflammation. Some of these cells can be targeted to reprogram their function, leading to resolution, or at least neutralization, of cancer-promoting chronic inflammation, thereby facilitating cancer rejection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available